Clear Labs Introduces Clear Dx SARS-CoV-2 Solution that Addresses and Overcomes Traditional Barriers to NGS

Clear Labs (San Carlos, CA, USA) introduced its new Clear Dx SARS-CoV-2 solution that addresses and overcomes traditional barriers to next-generation sequencing (NGS) at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo which explored the cutting-edge science and technology shaping the future of laboratory medicine.

The Clear Dx is a fully automated, NGS platform that offers complete characterization of SARS-CoV-2 and its variants of concern. Built to deliver accurate and near real-time results, Clear Dx is revolutionizing the way clinical and public health labs approach genomic and pathogen surveillance. The fully automated sequencing platform helps labs work quickly and efficiently, offering the agility to address the rapidly evolving COVID-19 pandemic and more productive time to perform other lab tasks.

Clear Dx allows labs to generate the same outcome repeatedly - which reduces workflow errors, increases the consistency of results, boosts your overall productivity, and ultimately improves genomic surveillance. With the company’s comprehensive Clear Dx workflow, labs can manage and interpret data—and act on it accordingly—without the need for bioinformatics specialists. Featured in the platform are data integration and connectivity solutions that help to streamline pathogen surveillance of SARS-CoV-2. Clear Dx’s comprehensive and fully automated sequencing platform significantly reduces the level of effort typically required for infectious disease surveillance.

Related Links:
Clear Labs 

Visit expo >

New

Gold Member

Pneumocystis Jirovecii Detection Kit

Pneumocystis Jirovecii Real Time RT-PCR Kit

Unit-Dose Packaging solution
HLX

New

Incubator

HettCube 120

New

Serum Toxicology Benzodiazepine Assay

DRI Serum Toxicology Benzodiazepine Assay